X0306 4 2022-06-02 0 0001557746 Aclaris Therapeutics, Inc. ACRS 0001172252 SCHIFF ANDREW N C/O ACLARIS THERAPEUTICS, INC. 640 LEE ROAD, SUITE 200 WAYNE PA 19087 1 0 0 0 Common Stock 2022-06-03 4 M 0 3356 A 19565 D Common Stock 634455 I By Aisling Capital IV LP Stock Option (Right to Buy) 14.48 2022-06-02 4 A 0 15750 0.00 A 2032-06-01 Common Stock 15750 15750 D Restricted Stock Units 2022-06-02 4 A 0 4507 0.00 A Common Stock 4507 4507 D Restricted Stock Units 2022-06-03 4 M 0 3356 0.00 D Common Stock 3356 0 D Each restricted stock unit represents a contingent right to receive one share of common stock of the issuer. The reportable securities are owned directly by Aisling Capital IV, LP ("Aisling"), and held indirectly by Aisling Capital Partners IV, LP ("Aisling GP"), as general partner of Aisling, Aisling Capital Partners IV LLC ("Aisling Partners"), as general partner of Aisling GP, and each of the individual managing members of Aisling Partners. The individual managing members (collectively, the "Managers") of Aisling Partners are Dr. Andrew Schiff and Steve Elms. Aisling GP, Aisling Partners, and the Managers share voting and dispositive power over the shares directly held by Aisling. Dr. Schiff disclaims beneficial ownership of these securities and this report is not an admission that he is the beneficial owner of such securities for purposes of Section 16 or for any other purpose, except to the extent of his pecuniary interest therein. This grant was made pursuant to the issuer's seventh amended and restated non-employee director compensation policy. The shares subject to this option will vest in twelve equal monthly installments commencing July 2, 2022, subject to Reporting Person's continuous service through each such date. The shares underlying these restricted stock units will vest on June 2, 2023, subject to the Reporting Person's continuous service through such date. The shares underlying these restricted stock units vested on June 3, 2022. /s/ Mark Ballantyne, Attorney-in-Fact 2022-06-06